Persisting Hyperbilirubinemia in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Chronically Treated with Eculizumab: The Role of Hepatocanalicular Transporter Variants

ConclusionsHyperbilirubinemia in PNH pts treated with eculizumab might not only be due to an insufficient response but rather a combination of mutations in hepatocanalicular transporter variants, Gilbert syndrome and extravascular hemolysis. Our findings warrant further studies concerning transporter and enzyme variants in PNH to determine their clinical significance.This article is protected by copyright. All rights reserved.

Source: European Journal of Haematology - July 10, 2017 Category: Hematology Authors: Ferras Alashkar, Susanne N Weber, Colin Vance, D örte Herich‐Terhürne, Ulrich Dührsen, Frank Lammert, Alexander Röth Tags: Original Article Source Type: research